For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.
INCLUDED IN THIS TRENDLINE
- Biotech startups face ‘trickle-down effects’ as sector’s IPO drought endures
- Undeterred by gene therapy’s struggles, a startup launches into a downturn
- How the biotech downturn is already affecting drug startups